Acura Pharmaceuticals Announces Settlement of Oxecta(R) Patent Litigation With Par Pharmaceutical and Impax Laboratories

PALATINE, IL–(Marketwired – Oct 9, 2013) – Acura Pharmaceuticals, Inc. (NASDAQ:ACUR), a specialty pharmaceutical company developing products intended to address medication abuse and misuse, announced today that it has entered into distinct Settlement Agreements with each of Par Pharmaceutical and Impax Laboratories, to settle Acura’s patent infringement action pending against them in the United States District Court for the District of Delaware. In the suit, Acura alleges that a generic Oxecta® product for which each of Par and Impax is separately seeking approval to market in the United States pursuant to an Abbreviated New Drug Application (ANDA) filing with the U.S. Food and Drug Administration (FDA) infringes a U.S. patent owned by Acura. Par is the first filer of an ANDA for a generic Oxecta® product and is entitled to the 180-day first filer exclusivity under applicable law and FDA regulations. 

Read the source article at

About the Author

Leave a Reply